Development of translational pharmacokinetic-pharmacodynamic models

被引:88
作者
Mager, D. E. [1 ]
Jusko, W. J. [1 ]
机构
[1] SUNY Buffalo, Dept Pharmaceut Sci, Buffalo, NY 14260 USA
关键词
D O I
10.1038/clpt.2008.52
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Contemporary models in the field of pharmacokinetic-pharmacodynamic (PK-PD) modeling often incorporate the fundamental principles of capacity limitation and operation of turnover processes to describe the time course of pharmacological effects in mechanistic terms. This permits the identification of drug- and system-specific factors that govern drug responses. There is considerable interest in utilizing mechanism-based PK-PD models in translational pharmacology, whereby in silico, in vitro, and preclinical data may be effectively coupled with relevant models to streamline the discovery and development of new therapeutic agents. These translational PK-PD models form the subject of this review.
引用
收藏
页码:909 / 912
页数:4
相关论文
共 33 条
[21]   Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-β1a monkeys [J].
Mager, DE ;
Neuteboom, B ;
Efthymiopoulos, C ;
Munafo, A ;
Jusko, WJ .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 306 (01) :262-270
[22]   Receptor-mediated pharmacokinetic/pharmacodynamic model of interferon-β 1a in humans [J].
Mager, DE ;
Jusko, WJ .
PHARMACEUTICAL RESEARCH, 2002, 19 (10) :1537-1543
[23]   Quantitative structure-pharmacokinetic/pharmacodynamic relationships [J].
Mager, Donald E. .
ADVANCED DRUG DELIVERY REVIEWS, 2006, 58 (12-13) :1326-1356
[24]   Prospective allometric scaling: Does the emperor have clothes? [J].
Mahmood, I .
JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 40 (04) :341-344
[25]   On the prediction of the human response: A recycled mechanistic pharmacokinetic/pharmacodynamic approach [J].
Meno-Tetang, GML ;
Lowe, PJ .
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2005, 96 (03) :182-192
[26]   Whole body pharmacokinetic models [J].
Nestorov, I .
CLINICAL PHARMACOKINETICS, 2003, 42 (10) :883-908
[27]   Prediction of the pharmacokinetics of succinylated human serum albumin in man from in vivo disposition data in animals and in vitro liver slice incubations [J].
Proost, JH ;
Bejaars, L ;
Inga, P ;
Swart, PJ ;
Kuipers, ME ;
Reker-Smit, C ;
Groothuis, GMM ;
Meijer, DKF .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 27 (2-3) :123-132
[28]   SPECIES, STRAIN AND SEX DIFFERENCES IN METABOLISM OF HEXOBARBITONE, AMIDOPYRINE, ANTIPYRINE AND ANILINE [J].
QUINN, GP ;
AXELROD, J ;
BRODIE, BB .
BIOCHEMICAL PHARMACOLOGY, 1958, 1 (02) :152-159
[29]   A mathematical description of the functionality of correction factors used in allometry for predicting human drug clearance [J].
Tang, HD ;
Mayersohn, M .
DRUG METABOLISM AND DISPOSITION, 2005, 33 (09) :1294-1296
[30]   A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model for the organophosphate insecticide chlorpyrifos in rats and humans [J].
Timchalk, C ;
Nolan, RJ ;
Mendrala, AL ;
Dittenber, DA ;
Brzak, KA ;
Mattsson, JL .
TOXICOLOGICAL SCIENCES, 2002, 66 (01) :34-53